PTO/SB/05 (08-03)
Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## UTILITY PATENT APPLICATION **TRANSMITTAL**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attomey Docket No. 21663-00212-US2 Pooran Chand CYCLOPENTENE NUCLEOSIDES, PREPARATION THEREOF AND USE AS INHIBITORS OF RNA VIRAL POLYMERASES

Expre	ess Mail Label No.						
APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents.	MS Patent Application Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450						
1. X Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original, and a duplicate for fee processing) 2. X Applicant claims small entity status. See 37 CFR 1.27. 3. X Specification [Total Pages 21]  (preferred arrangement set forth below) - Descriptive title of the invention - Cross Reference to Related Applications - Statement Regarding Fed sponsored R & D - Reference to sequence listing, a table, or a computer program listing appendix - Background of the Invention - Brief Summary of the Invention - Brief Description - Ctaim(s) - Detailed Description - Ctaim(s) - Abstract of the Disclosure  4. Drawing(s) (35 U.S.C. 113) [Total Sheets]	7. CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)  8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)  a. Computer Readable Form (CRF)  b. Specification Sequence Listing on:  i. CD-ROM or CD-R (2 copies); or ii. Paper c. Statements verifying identity of above copies  ACCOMPANYING APPLICATION PARTS  9. Assignment Papers (cover sheet & document(s))  10. 37 CFR 3.73(b) Statement (when there is an assignee)  11. English Translation Document (if applicable)						
5. Oath or Declaration [Total Sheets]  a. Newly executed (original or copy)  b. Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 18 completed)  i. DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).  6. X Application Data Sheet. See 37 CFR 1.76	12. Information Disclosure Copies of IDS Statement (IDS)/PTO-1449 Citations  13. Preliminary Amendment  14. X Return Receipt Postcard (MPEP 503) (Should be specifically itemized)  15. Certified Copy of Priority Document(s) (if foreign priority is claimed)  16. Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.  17. Other:						
18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in the first sentence of the specification following the title, or in an Application Data S heet under 37 CFR 1.76:  Continuation  Divisional  Continuation-in-part (CIP) of prior application No.:  Prior application information: Examiner  Art Unit:  For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.  19. CORRESPONDENCE ADDRESS							
X Customer Number: 30678	OR Correspondence address below						
Name							
Address	Ti- Code						
City         State           Country         Telephone	Zip Code Fax						
Name (Print/Type) Bur/ton A. Amernick/	Registration No. (Attorne y/Agent) 24,852						
Signature	Date 1 -2 6-24						

PTO/SB/17 (10-03)

Approved for use through 7/31/2006. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

CEE TO A NOMITTAL	l	Complete if Known						
FEE TRANSMITTAL	· [	Application Number Not Yet Assigned						
for FY 2004		Filing Date			Concurrently Herewith	Concurrently Herewith		
	First Named Inventor			Inven	tor Pooran Chand	Pooran Chand		
Effective 10/01/2003, Patent fees are subject to annual revision.		Examiner Name		ame	Not Yet Assigned	Not Yet Assigned		
X Applicant claims small entity status. See 37 CFR 1.27		Art Unit			N/A	N/A		
TOTAL AMOUNT OF PAYMENT (\$) 385.00		Attorney Docket No. 21663-00212-US2						
METHOD OF PAYMENT (check all that apply)	<del>- '</del>	FEE CALCULATION (continued)						
Check Credit Money Other Money	2 1	DDITI			,			
Card Order Other	lone 3. ADDITIONAL FEES							
X Depos it Account:		Entitu	Cmall	Entity				
Deposit Account · 22-0185	Fee	Entity Fee	Fee	Fee	For Departmen			
Number	Code	(\$)	Code	(\$)	Fee Description	Fee Paid		
Deposit Account Connolly Bove Lodge & Hutz LLP	1051	130	2051	65	Surcharge – late filing fee or oath			
Name	1052	50	2052	25	Surcharge - late provisional filing fee or cover			
The Director is authorized to: (check all that apply)	4050	400	4050	400	sheet.			
X Cred it any overpayments	1053	130	1053	130	Non-English specification			
X Charge any additional fee(s) or any underpayment of fee(s)	1812	2,520	1812		For filing a request for ex parte reexamination			
Charge fee(s) indicated below, except for the filling fee	1804	920*	1804	320	Requesting publication of SIR prior to Examiner action			
to the above-identified deposit account.	1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action			
FEE CALCULATION	1251	110	2251	55	Extension for reply within first month			
1. BASIC FILING FEE	1252	420	2252	210	Extension for reply within second month			
Large Entity	1253	950	2253		Extension for reply within third month			
Code (\$) Code (\$)	1254	1,480	2254	740	Extension for reply within fourth month			
1001 770 2001 385 Utility filing fee 385.00	1255	2,010	2255		E xtension for reply within fifth month			
1002 340 2002 170 Design filing fee	1401	330	2401		Notice of Appeal			
1003 530 2003 265 Plant filing fee 1004 770 2004 385 Reissue filing fee	1402 1403	330 290	2402 2403		Filing a brief in support of an appeal			
1004 770 2004 385 Reissue filing fee 1005 160 2005 80 Provisional filing fee	1451	1,510	1451		Request for oral hearing P etition to institute a public use proceeding			
	1452	110	2452	55	Petition to revive – unavoidable			
SUBTOTAL (1) (\$) 385.00	1453	1,330	2453	665	Petition to revive - unintentional			
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE	1501	1,330	2501	665	Utility issue fee (or reissue)			
Extra Fee from Claims below Fee Paid	1502	480	2502	240	Design issue fee			
Total Claims 6 -20** = x = 0.00	1503	640	2503	320	Plant issue fee			
Independent 1 -3** = X = 0.00	1460	130	1460	130	Petitions to the Commissioner			
Multiple Dependent =	1807	50	1807	50	Processing fee under 37 CFR 1.17(q)			
Large Entity Small Entity	1806	180	1806	180	Submission of Information Disclosure Stmt			
Fee Fee Fee Code (\$) Fee Description	8021	40	8021	40	Recording each patent assignment per property (times number of properties)			
1202 18 2202 9 Claims in excess of 20	1809	770	2809	385	Filing a submission after final rejection			
1201 86 2201 43 Independent claims in excess of 3					(37 CFR 1.129(a)) For each additional invention to be			
1203 290 2203 145 Multiple dependent claim, if not paid	1810	770	2810	385	examined (37CFR 1.129(b))			
1204 86 2204 43 ** Reissue independent claims over original patent	1801	770	2801	385	Request for Continued Examination (RCE)			
1205 18 2205 9 ** Reissue claims in excess of 20	1802	900	1802	960	Request for expedited examination of a design application			
and over original patent	Other fee (specify)							
SUBTOTAL (2) (\$) 0.00 *Reduced by Basic Filing Fee Paid SUBTOTAL (3) (\$) 0.0								
**or number previously paid, if greater; For Reissues, see above								
SUBMITTED BY (Complete (if applicable))								
Name (Print/Type) Burton A. Amernick Registration No. (Attorney/Agent) 24,852 Telephone (202) 331-7111								
Signature // / /					Date 2-26-04	/		